Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.5300 (-2.69%) ($2.5200 - $2.6900) on Tue. Mar. 1, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.46% (three month average) | RSI | 42 | Latest Price | $2.5300(-2.69%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | HTBX declines -5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(53%) VWO(52%) ONLN(51%) FXI(50%) IPO(50%) | Factors Impacting HTBX price | HTBX will decline at least -2.23% in a week (0% probabilities). VXX(-53%) VIXM(-53%) UUP(-26%) TBT(-14%) USO(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.23% (StdDev 4.46%) | Hourly BBV | 1 () | Intraday Trend | -1.9% | | | |
|
1 - 5 Day Possible Target | $-7.24(-386.17%) | Resistance Level | $2.72 | 5 Day Moving Average | $2.55(-0.78%) | 10 Day Moving Average | $2.63(-3.8%) | 20 Day Moving Average | $2.72(-6.99%) | To recent high | -40% | To recent low | 1.2% | Market Cap | $278m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |